NASDAQ:ICLR - Icon Stock Price, News, & Analysis

$145.09
+0.33 (+0.23 %)
(As of 06/18/2019 04:00 PM ET)
Today's Range
$144.66
Now: $145.09
$146.17
50-Day Range
$134.47
MA: $140.45
$145.30
52-Week Range
$118.10
Now: $145.09
$155.33
Volume100,423 shs
Average Volume291,383 shs
Market Capitalization$7.83 billion
P/E Ratio23.07
Dividend YieldN/A
Beta0.54
ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. Read More…

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ICLR
CUSIPN/A
Phone353-1291-2000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.60 billion
Cash Flow$7.7258 per share
Book Value$25.09 per share

Profitability

Net Income$322.66 million

Miscellaneous

Employees13,670
Market Cap$7.83 billion
Next Earnings Date7/24/2019 (Estimated)
OptionableOptionable

Receive ICLR News and Ratings via Email

Sign-up to receive the latest news and ratings for ICLR and its competitors with MarketBeat's FREE daily newsletter.

Icon (NASDAQ:ICLR) Frequently Asked Questions

What is Icon's stock symbol?

Icon trades on the NASDAQ under the ticker symbol "ICLR."

How were Icon's earnings last quarter?

Icon Plc (NASDAQ:ICLR) released its earnings results on Wednesday, May, 1st. The medical research company reported $1.63 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $1.60 by $0.03. The medical research company had revenue of $674.85 million for the quarter, compared to analysts' expectations of $668.93 million. Icon had a net margin of 12.56% and a return on equity of 25.71%. Icon's quarterly revenue was up 8.8% on a year-over-year basis. During the same quarter last year, the company earned $1.44 EPS. View Icon's Earnings History.

When is Icon's next earnings date?

Icon is scheduled to release their next quarterly earnings announcement on Wednesday, July 24th 2019. View Earnings Estimates for Icon.

What guidance has Icon issued on next quarter's earnings?

Icon updated its FY19 earnings guidance on Wednesday, May, 1st. The company provided EPS guidance of $6.75-6.95 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $6.83. The company issued revenue guidance of $2.76-2.84 billion, compared to the consensus revenue estimate of $2.79 billion.

What price target have analysts set for ICLR?

10 analysts have issued twelve-month price objectives for Icon's stock. Their predictions range from $136.00 to $168.00. On average, they anticipate Icon's stock price to reach $154.6250 in the next twelve months. This suggests a possible upside of 6.6% from the stock's current price. View Analyst Price Targets for Icon.

What is the consensus analysts' recommendation for Icon?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Icon in the last year. There are currently 1 sell rating, 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Icon.

Has Icon been receiving favorable news coverage?

Press coverage about ICLR stock has trended neutral this week, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Icon earned a media sentiment score of 0.1 on InfoTrie's scale. They also assigned media stories about the medical research company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the immediate future. View News Stories for Icon.

Are investors shorting Icon?

Icon saw a drop in short interest in May. As of May 15th, there was short interest totalling 588,500 shares, a drop of 16.7% from the April 15th total of 706,600 shares. Based on an average trading volume of 313,400 shares, the days-to-cover ratio is presently 1.9 days. Approximately 1.1% of the company's stock are sold short. View Icon's Current Options Chain.

Who are some of Icon's key competitors?

What other stocks do shareholders of Icon own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Icon investors own include Pfizer (PFE), Gilead Sciences (GILD), Visa (V), NVIDIA (NVDA), Mastercard (MA), Netflix (NFLX), Alibaba Group (BABA), Adobe (ADBE), Amgen (AMGN) and Alphabet (GOOG).

Who are Icon's key executives?

Icon's management team includes the folowing people:
  • Dr. Steven A. Cutler, CEO & Director (Age 59)
  • Mr. Brendan Brennan, Chief Financial Officer (Age 40)
  • Jonathan Curtain, VP of Corp. Fin. & Investor Relations
  • Mr. Thomas O'Leary, Chief Information Officer
  • Mr. Diarmaid Cunningham, Chief Admin. Officer, Gen. Counsel, Exec. VP & Company Sec. (Age 44)

Who are Icon's major shareholders?

Icon's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include WCM Investment Management LLC (6.15%), Clearbridge Investments LLC (4.36%), Acadian Asset Management LLC (3.98%), Boston Partners (2.79%), Pendal Group Ltd (2.61%) and Wasatch Advisors Inc. (2.59%).

Which major investors are selling Icon stock?

ICLR stock was sold by a variety of institutional investors in the last quarter, including WCM Investment Management LLC, Blackcrane Capital LLC, New York State Common Retirement Fund, Wells Fargo & Company MN, Wasatch Advisors Inc., FMR LLC, State of Tennessee Treasury Department and Janus Henderson Group PLC.

Which major investors are buying Icon stock?

ICLR stock was bought by a variety of institutional investors in the last quarter, including Comgest Global Investors S.A.S., Clearbridge Investments LLC, Boston Partners, Ellis Investment Partners LLC, Ellis Investment Partners LLC, Marshall Wace North America L.P., AJO LP and Peregrine Capital Management LLC.

How do I buy shares of Icon?

Shares of ICLR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Icon's stock price today?

One share of ICLR stock can currently be purchased for approximately $145.09.

How big of a company is Icon?

Icon has a market capitalization of $7.83 billion and generates $2.60 billion in revenue each year. The medical research company earns $322.66 million in net income (profit) each year or $6.29 on an earnings per share basis. Icon employs 13,670 workers across the globe.View Additional Information About Icon.

What is Icon's official website?

The official website for Icon is http://www.iconplc.com/.

How can I contact Icon?

Icon's mailing address is SOUTH COUNTY BUSINESS PARK LEOPARDSTOWN, DUBLIN L2, 00000. The medical research company can be reached via phone at 353-1291-2000.


MarketBeat Community Rating for Icon (NASDAQ ICLR)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  468 (Thanks for Voting!)
Underperform Votes:  379 (Thanks for Voting!)
Total Votes:  847
MarketBeat's community ratings are surveys of what our community members think about Icon and other stocks. Vote "Outperform" if you believe ICLR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ICLR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel